UBS AM
TNGX icon

UBS AM’s Tango Therapeutics TNGX Stock Holding History

UBS AM’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4M Buy
127,801
+52,084
+69% +$1.29M ﹤0.01% 1718
2026
Q1 		$1.58M Buy
75,717
+34,264
+83% +$477K ﹤0.01% 2149
2025
Q4 		$367K Buy
+41,453
New +$357K ﹤0.01% 2382
2025
Q1 		– Sell
-76,551
Closed -$237K – 2701
2024
Q4 		$237K Buy
76,551
+1,249
+2% +$5.8K ﹤0.01% 2629
2024
Q3 		$580K Sell
75,302
-3,420
-4% -$32.6K ﹤0.01% 2607
2024
Q2 		$675K Buy
78,722
+66,522
+545% +$514K ﹤0.01% 2546
2024
Q1 		$96.9K Hold
12,200
– – ﹤0.01% 2494
2023
Q4 		$121K Hold
12,200
– – ﹤0.01% 2519
2023
Q3 		$137K Sell
12,200
-20,797
-63% -$127K ﹤0.01% 2546
2023
Q2 		$130K Hold
32,997
– – ﹤0.01% 2616
2023
Q1 		$130K Buy
32,997
+20,797
+170% +$121K ﹤0.01% 2616
2022
Q4 		$88.5K Hold
12,200
– – ﹤0.01% 2500
2022
Q3 		$44.2K Hold
12,200
– – ﹤0.01% 2717
2022
Q2 		$55.3K Hold
12,200
– – ﹤0.01% 2669
2022
Q1 		$92.5K Hold
12,200
– – ﹤0.01% 2745
2021
Q4 		$133K Buy
+12,200
New +$147K ﹤0.01% 2803

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

UBS AM's TNGX Position: Q2 2026 in Review

UBS AM increased its Tango Therapeutics (TNGX) stake by 69% in Q2 2026, buying an estimated $1.29M and bringing the position to 127,801 shares worth $4M. The position accounts for ﹤0.01% of the portfolio, ranked #1718.

UBS AM first reported a position in TNGX in Q4 2021 and has held it in 16 quarters since. 247 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • UBS AM held 127,801 shares of Tango Therapeutics worth $4M as of Q2 2026.
  • UBS AM bought 52,084 Tango Therapeutics shares in Q2 2026, an estimated $1.29M.
  • Tango Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1718 holding.
  • UBS AM first reported a position in Tango Therapeutics in Q4 2021 and has held it in 16 quarters since.
  • 247 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.